SNDS: What is it and why using it?

Please find below a publication from PELyon on LinkedIn about the possibilities offered by the SNDS and the ESND in terms of Real World Evidence.
Do not hesitate to contact us to determine how these databases can fulfill your needs and what are the best options for your upcoming RWE studies.

New Article

We are pleased to share our new article written in collaboration with the Hospices Civils de Lyon:

Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France,

published in Frontiers in Public Health.

PELyon has published a new scientific article

PELyon is happy to share its new article:

Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis,

published in Respiratory Medecine and Research.

Great thanks to the co-authors, to the CNAM for the access to SNDS data and to F. Hoffmann-La Roche company for its trust.